March 02, 2015 2:20 PM ET

Capital Markets

Company Overview of Tekla Life Sciences Investors

Company Overview

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as strong market position for services or products, experienced business management, recognized technological expertise,...

2 Liberty Square

9th Floor

Boston, MA 02109

United States

Founded in 1992





Key Executives for Tekla Life Sciences Investors

Principal Executive Officer, President, Trustee and Member of Valuation Committee
Age: 61
Principal Financial Officer, Chief Compliance Officer, Secretary and Treasurer
Age: 46
Assistant Treasurer
Age: 42
Compensation as of Fiscal Year 2014.

Tekla Life Sciences Investors Key Developments

Tekla Life Sciences Investors Declares a Stock Distribution, Payable on March 31, 2015

On February 20, 2015, Tekla Life Sciences Investors declared a stock distribution of $0.50 per share. The record date for the stock distribution is March 2, 2015 and the payable date is March 31, 2015. The Fund will trade ex-distribution on February 26, 2015.

H&Q Life Sciences Investors has Changed its Name to Tekla Life Sciences Investors

H&Q Life Sciences Investors changed its name to Tekla Life Sciences Investors.

H&Q Life Sciences Investors, Annual General Meeting, Jun 09, 2014

H&Q Life Sciences Investors, Annual General Meeting, Jun 09, 2014., at 08:30 US Eastern Standard Time. Location: Downtown Harvard Club of Boston, One Federal Street. Agenda: To consider the election of Trustees of the Fund; and to approve the ratification or rejection of the selection of Deloitte & Touche LLP as the independent registered public accountants of the fund for the fiscal year ending September 30, 2014; and to approve the transaction of such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.

Similar Private Companies By Industry

Company Name Region
Sarius Capital Group United States
Midwood Securities, Inc. United States
Moroney Management Ltd. United States
Arcady Bay Partners, LLC United States
Ibercaja Finance Limited United States

Recent Private Companies Transactions

December 8, 2014
Cubist Pharmaceuticals Inc.
Private Placement
December 5, 2014
CardioKinetix, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tekla Life Sciences Investors, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at